
Every cancer patient is different. Their treatment should be too.

BioReperia

Precision Powered by Biology




THE PROBLEM: Treatment chosen on averages

BioReperia

Most MIBC patients get months of pre-surgery treatment that nobody can predict will work

OUT OF 100 PATIENTS GIVEN NEOADJUVANT TREATMENT


Cisplatin chemotherapy



65 of 100

never reach a pathologic complete response[1]

EV + pembrolizumab



45 of 100

never reach a pathologic complete response[2]

HOW LONG UNTIL THE CLINICIAN KNOWS

Today

~4 months of treatment, then surgery shows if it worked

ZTX®PREDICT

5 days, before the first dose

0

approved functional companion diagnostics for MIBC today. Fewer than 1 in 10 patients get genomics-guided treatment, and genomics shows mutations, not drug response.[3] [4]


A non-responder finds out too late: toxicity taken, surgery delayed, and the window for an alternative closing.

1 Rosenblatt et al., 2012 · 2 Ghoreifi et al., 2026 · 3 Saito et al., 2026 · 4 Zeredes et al., 2025 · EV = enfortumab vedotin · MIBC = muscle-invasive bladder cancer

THE SOLUTION: The patient's own tumour, tested

BioReperia

A living readout of which drug shrinks this cancer, back to the clinician in 5 days



Day 0
Biopsy taken at TURBT and shipped in our collection kit

Day 1–2
Tumour cells labelled and implanted in zebrafish larvae

Day 2–5
Standard-of-care regimens tested side by side

Day 5
Report to the urologist: which drug shrank this tumour


Why it works: a whole living organism keeps the tumour and its surroundings intact. Mouse models take ~6 months. Organoids take weeks and lose the microenvironment.

THE EVIDENCE: More than 500 biopsies tested

BioReperia

370 patients in 7 clinics in Sweden and Greece, plus peer-reviewed results in two cancers

PATIENTS TESTED IN CLINICAL SETTINGS · EACH DOT = ONE PATIENT



171	153	30	16
Bladder lead indication	Colorectal	Liver metastases from colorectal	Pancreatic

Still maturing: final sensitivity and specificity depend on clinical outcomes in these cohorts. The PREDICT-MIBC study is built to confirm them.

>95% of bladder cancer samples gave a valid result

>80% accuracy predicting treatment outcome

PRELIMINARY

PEER-REVIEWED

Bladder cancer · Cells 2023

ZTX® response to BCG matched the clinical outcome in 3 of 4 patients

Ovarian cancer · npj Precis Oncol 2024

All 4 ZTX® carboplatin responders stayed progression-free past 2 years

Kowald S, Huge Y, et al. Cells 2023;12:508 · Lindahl G, Fjellander S, et al. npj Precis Oncol 2024;8:53

THE OPPORTUNITY: Better outcomes, open market

BioReperia

Treating only predicted responders could nearly double the share with a good prognosis


Standard plan, all patients treated



35 of 100

with a good prognosis

Only ZTX®PREDICT responders treated




67 of 100

with a good prognosis

■ good prognosis ■ toxicity and delay, no benefit

LAUNCH MARKETS · NEW MIBC PATIENTS A YEAR



21K
United States

7K
Germany

0.6K
Sweden

~29K

patients a year, and up to half cannot take cisplatin

€5,000

per test, 70% gross margin

€29M

revenue in launch markets by 2035 at 20% uptake

€110M

adding rest of Europe and Asia (unverified)

Prognosis split modelled from early bladder cancer data, to be confirmed in PREDICT-MIBC. Incidence: SEER 2026, RKI 2026, RCC 2026, Nielsen et al., 2014. Rest of Europe and Asia: GLOBOCAN 2022 × 25%.

THE PLAN: EU launch 2030, US launch 2031

BioReperia

Built on 10 years of platform work and a CRO business that already earns revenue

2027 Start

Round closes
First patient, EU
IP filing
Bladder PoC published

2028 Study

Tranche 2
US CLIA lab partner
EU readout
First patient, US

2029 Apply

IVDR application
BioReperia Inc

2030 Launch

CE mark
EU launch
FDA application

2031 Scale

FDA De Novo
US launch
Payer contracts, US

WHY BIOREPERIA

€2.7M
cumulative sales from ZTX®ONCOLEADS, our pharma CRO service

15+
countries with repeat customers

10 years
of platform development, raw data and SOPs we own

18+ years
pharma experience in the CEO, with a PhD-led science team

ZTX®PREDICT was CE-marked under IVDD (2022–2026). The IVDR application renews it under the new regulation.

THE ASK: €5M to CE mark and launch

BioReperia

Released in two tranches, each tied to a milestone that lifts the value of the company

€5M

total raise

€1.5M on close
€3.5M at first patient in

€1.5M

On close

IP filing, notified body, IVDR preparation, FDA pre-submission, PREDICT-MIBC start-up

€3.5M

First patient in, Q3 2027

Study execution, IVDR submission, US pathway, payer evidence

Value inflection

Readout + CE mark

Launch in Sweden, Germany and the US, reimbursement, lab scale-up


Company value rises at each milestone

BioReperia

Join us on our mission:

Cancer is not one disease. And patients are not statistics.

Yet treatment is still chosen by averages: generalized protocols, fragmented data, trial and error. We believe every patient deserves the treatment most likely to work for them. Not the one that works for "most people".



Contact information: www.bioreperia.com/emmelie.persson@bioreperia.com